Verastem Stock Fundamentals
| VSTM Stock | USD 4.00 0.07 1.78% |
Verastem fundamentals help investors to digest information that contributes to Verastem's financial success or failures. It also enables traders to predict the movement of Verastem Stock. The fundamental analysis module provides a way to measure Verastem's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Verastem stock.
At this time, Verastem's Interest Expense is very stable compared to the past year. As of the 22nd of November 2024, Selling General Administrative is likely to grow to about 35.8 M, while Other Operating Expenses is likely to drop about 79.9 M. Verastem | Select Account or Indicator |
Verastem Company Return On Equity Analysis
Verastem's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Verastem Return On Equity | -1.37 |
Most of Verastem's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Verastem is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Verastem Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Verastem has a Return On Equity of -1.3687. This is 94.29% lower than that of the Biotechnology sector and 96.25% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Verastem Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Verastem's current stock value. Our valuation model uses many indicators to compare Verastem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Verastem competition to find correlations between indicators driving Verastem's intrinsic value. More Info.Verastem is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, Verastem's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Verastem by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Verastem Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Verastem's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Verastem could also be used in its relative valuation, which is a method of valuing Verastem by comparing valuation metrics of similar companies.Verastem is currently under evaluation in return on equity category among its peers.
Verastem Current Valuation Drivers
We derive many important indicators used in calculating different scores of Verastem from analyzing Verastem's financial statements. These drivers represent accounts that assess Verastem's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Verastem's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 99.9M | 326.6M | 357.5M | 77.5M | 69.7M | 66.2M | |
| Enterprise Value | 164.0M | 281.4M | 259.5M | 29.6M | 34.0M | 32.3M |
Verastem ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Verastem's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Verastem's managers, analysts, and investors.Environmental | Governance | Social |
Verastem Fundamentals
| Return On Equity | -1.37 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (11.45) % | ||||
| Current Valuation | 118.09 M | ||||
| Shares Outstanding | 44.51 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 59.92 % | ||||
| Number Of Shares Shorted | 2.46 M | ||||
| Price To Earning | (3.02) X | ||||
| Price To Book | 15.25 X | ||||
| Price To Sales | 17.49 X | ||||
| Gross Profit | 2.6 M | ||||
| EBITDA | (83.17 M) | ||||
| Net Income | (87.37 M) | ||||
| Cash And Equivalents | 94.31 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 41.56 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 4.87 X | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (86.46 M) | ||||
| Short Ratio | 2.31 X | ||||
| Earnings Per Share | (3.14) X | ||||
| Price To Earnings To Growth | (1.89) X | ||||
| Target Price | 11.13 | ||||
| Number Of Employees | 73 | ||||
| Beta | 0.14 | ||||
| Market Capitalization | 174.91 M | ||||
| Total Asset | 149.72 M | ||||
| Retained Earnings | (824.89 M) | ||||
| Working Capital | 117.3 M | ||||
| Current Asset | 110.84 M | ||||
| Current Liabilities | 10.11 M | ||||
| Net Asset | 149.72 M |
About Verastem Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Verastem's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verastem using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verastem based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 7.4 M | 7.3 M | |
| Cost Of Revenue | 62 K | 58.9 K | |
| Stock Based Compensation To Revenue | 2.10 | 1.10 | |
| Sales General And Administrative To Revenue | 2.60 | 2.31 | |
| Research And Ddevelopement To Revenue | 17.53 | 18.40 | |
| Capex To Revenue | 0.11 | 0.10 | |
| Revenue Per Share | 0.16 | 0.18 | |
| Ebit Per Revenue | (32.31) | (30.69) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Verastem Piotroski F Score and Verastem Altman Z Score analysis. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share 0.331 | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (1.37) |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.